Glen Eagle Advisors’s Biogen BIIB Stock Holding History

Glen Eagle Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-3	Closed	-$956	–	685
2017 Q4	$956	Hold	3	–	–	﹤0.01%	606
2017 Q3	$939	Buy	+3	New	+$888	﹤0.01%	614

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Glen Eagle Advisors's BIIB Position: Q1 2018 in Review

Glen Eagle Advisors sold out of Biogen (BIIB) in Q1 2018, closing a stake of 3 shares — an estimated $956 sold.

Glen Eagle Advisors first reported a position in BIIB in Q3 2017 and held it in 2 quarters. The position peaked at $956 in Q4 2017. 1,103 funds tracked by Wall St. Rank hold BIIB as of Q1 2018.

Glen Eagle Advisors reported no remaining Biogen position as of Q1 2018 after selling out during the quarter.
Glen Eagle Advisors sold 3 Biogen shares in Q1 2018, an estimated $956.
Glen Eagle Advisors first reported a position in Biogen in Q3 2017 and held it in 2 quarters.
Glen Eagle Advisors's Biogen position peaked at $956 in Q4 2017.
1,103 funds tracked by Wall St. Rank held Biogen as of Q1 2018.

Based on Glen Eagle Advisors's 13F filing for Q1 2018, filed 13 Aug 2024.